<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3859">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04456088</url>
  </required_header>
  <id_info>
    <org_study_id>BAI_COV19_01_CAN</org_study_id>
    <nct_id>NCT04456088</nct_id>
  </id_info>
  <brief_title>Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (CANADA Trial)</brief_title>
  <official_title>Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beyond Air Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beyond Air Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this open label, 2-phase, study is to obtain information on the safety of 80&#xD;
      ppm and the safety and efficacy of 150 ppm Nitric Oxide given in addition to the standard of&#xD;
      care of patients with COVID-19 caused by SARS-CoV-2.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Terminated (halted prematurely)&#xD;
  </why_stopped>
  <start_date type="Anticipated">July 15, 2020</start_date>
  <completion_date type="Anticipated">December 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a two phase study. The first 10 subjects will be treated with 80ppm NO; The remaining 40 subjects will be randomized in 1:1 ratio with subjects receiving 150 NO+SST or the SST alone.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to deterioration</measure>
    <time_frame>up to 14 days</time_frame>
    <description>Time to deterioration as measured by any one of the following:&#xD;
need for non-invasive ventilation&#xD;
need for high flow nasal cannula (HFNC) or&#xD;
need for intubation&#xD;
Death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to stable oxygen saturation</measure>
    <time_frame>up to 14 days</time_frame>
    <description>Time to patient having stable oxygen saturation (SpO2) of greater than 92% for longer than 3 hr on room air</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Treatment Emergent Adverse Events and SAEs</measure>
    <time_frame>30 days after last inhalation treatment</time_frame>
    <description>Treatment Emergent Adverse Events and SAEs - safety evaluation for 30 days after last inhalation treatment</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>COVID-19</condition>
  <condition>SARS-CoV 2</condition>
  <condition>Respiratory Disease</condition>
  <condition>Pneumonia, Viral</condition>
  <condition>Corona Virus Infection</condition>
  <arm_group>
    <arm_group_label>Phase 1- Nitric oxide treatment- 80ppm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2- Group 1- Nitric oxide treatment- 150ppm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2- Group 2- control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of Care</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>150 ppm Nitric Oxide delivered through LungFit Delivery System</intervention_name>
    <description>Nitric Oxide delivered via LungFit system. Patients will receive inhalations of 150 ppm for 40 minutes 4 time per day plus standard supportive care.</description>
    <arm_group_label>Phase 2- Group 1- Nitric oxide treatment- 150ppm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>80 ppm Nitric Oxide delivered through LungFit Delivery System</intervention_name>
    <description>Nitric Oxide delivered via LungFit system. Patients will receive inhalations of 80 ppm for 40 minutes 4 time per day plus standard supportive care.</description>
    <arm_group_label>Phase 1- Nitric oxide treatment- 80ppm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients (male and female) admitted to the hospital for COVID-19&#xD;
&#xD;
          2. Patients with oxygen saturation less than 93 % on room air&#xD;
&#xD;
          3. Shortness of breath, with symptom onset within the previous 8 days.&#xD;
&#xD;
          4. Ability to understand and comply with study requirements .&#xD;
&#xD;
          5. Signed informed consent by subject&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who are treated with or require high flow nasal cannula, CPAP, intubation,&#xD;
             mechanical ventilation, or tracheostomy&#xD;
&#xD;
          2. Diagnosis of acute respiratory distress syndrome&#xD;
&#xD;
          3. Breastfeeding or pregnancy as evidenced by a positive pregnancy test.&#xD;
&#xD;
          4. Subjects diagnosed with immunodeficiency, with history of congestive or unstable heart&#xD;
             disease, left ventricular dysfunction (LVEF &lt;40%) or myocardial damage, severe&#xD;
             pulmonary hypertension and/or unstable hypertension&#xD;
&#xD;
          5. History of frequent epistaxis (&gt;1 episode/month).&#xD;
&#xD;
          6. Significant hemoptysis during the last 30 days prior to enrollment&#xD;
&#xD;
          7. Methemoglobin level &gt;3% at screening&#xD;
&#xD;
          8. Patients on systemic steroids (any formulation) within 30 days prior to enrollment.&#xD;
&#xD;
          9. History of daily, continuous oxygen supplementation&#xD;
&#xD;
         10. Patients with BMI greater than or equal to 36&#xD;
&#xD;
         11. Patient receiving drugs that have a contraindication with NO,&#xD;
&#xD;
         12. Patients with clinically significant anemia, e.g., Hb &lt;100 g/L and thrombocytopenia,&#xD;
             e.g., Platelets &lt;75 thousand cells/mcL.&#xD;
&#xD;
         13. Presence of a condition or abnormality that in the opinion of the Investigator would&#xD;
             compromise the safety of the subject or the quality of the data, e.g., known or&#xD;
             suspected thalassemia, sickle cell disease or other diseases associated with poor&#xD;
             oxygen carrying capacity.&#xD;
&#xD;
         14. The subject is identified by the investigator as being unable or unwilling to perform&#xD;
             study procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Asher Tal, MD</last_name>
    <role>Study Director</role>
    <affiliation>Beyond Air</affiliation>
  </overall_official>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 1, 2020</study_first_submitted>
  <study_first_submitted_qc>July 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2020</study_first_posted>
  <last_update_submitted>January 21, 2021</last_update_submitted>
  <last_update_submitted_qc>January 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Pneumonia, Viral</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

